이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Checkpoint Therapeutics 배당금

배당금 기준 확인 0/6

Checkpoint Therapeutics 배당금을 지급한 기록이 없습니다.

주요 정보

n/a

배당 수익률

n/a

지급 비율

업계 평균 수익률	1.9%
다음 배당금 지급일	n/a
전 배당일	n/a
주당 배당금	n/a
주당 순이익	-US$0.94
배당 수익률 예측	n/a

최근 배당금 업데이트

업데이트 없음

Recent updates

We're A Little Worried About Checkpoint Therapeutics' (NASDAQ:CKPT) Cash Burn Rate

Sep 20

Checkpoint: Strong Data, But Comes With Risks

Sep 08

Checkpoint Therapeutics GAAP EPS of -$0.16 in-line, revenue of $0.02M beats by $0.01M

Aug 12

Is Checkpoint Therapeutics (NASDAQ:CKPT) In A Good Position To Deliver On Growth Plans?

May 18

Checkpoint Therapeutics: Potential Upside Based On Marketing Application Submissions

Apr 18

Companies Like Checkpoint Therapeutics (NASDAQ:CKPT) Are In A Position To Invest In Growth

Feb 15

Checkpoint Therapeutics: Another Buying Opportunity Following Cosibelimab's Impressive Topline Results

Jan 28

Checkpoint Therapeutics: Pullback Provides Opportunity To Add Ahead Of Cosibelimab's Data Readout

Nov 26

Checkpoint Therapeutics (NASDAQ:CKPT) Is In A Good Position To Deliver On Growth Plans

Oct 30

We're Not Very Worried About Checkpoint Therapeutics' (NASDAQ:CKPT) Cash Burn Rate

Jul 17

It's Unlikely That Checkpoint Therapeutics, Inc.'s (NASDAQ:CKPT) CEO Will See A Huge Pay Rise This Year

Jun 02

The Checkpoint Therapeutics (NASDAQ:CKPT) Share Price Is Up 141% And Shareholders Are Boasting About It

Mar 11

Have Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) Insiders Been Selling Their Stock?

Feb 06

Do Institutions Own Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) Shares?

Jan 27

결제의 안정성과 성장

배당금 데이터 가져오기

안정적인 배당: 과거에 CKPT 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.

배당금 증가: CKPT 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.

시장 대비 배당 수익률

Checkpoint Therapeutics 시장 대비 배당 수익률

CKPT 배당 수익률은 시장과 어떻게 비교되나요?
세그먼트	배당 수익률
회사 (CKPT)	n/a
시장 하위 25% (US)	1.4%
시장 상위 25% (US)	4.3%
업계 평균 (Biotechs)	1.9%
애널리스트 예측 (CKPT) (최대 3년)	n/a

주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 CKPT 의 배당 수익률을 평가할 수 없습니다.

고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 CKPT 의 배당 수익률을 평가할 수 없습니다.

주주에 대한 수익 배당금

수익 보장: 배당금 지급이 수익으로 충당되는지 확인하기 위해 CKPT 의 지급 비율을 계산하기에는 데이터가 부족합니다.

주주에 대한 현금 배당금

현금 흐름 범위: CKPT 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.

Checkpoint Therapeutics 배당금

배당금 기준 확인 0/6

주요 정보

최근 배당금 업데이트

Recent updates

Checkpoint Therapeutics, Inc. Announces Cosibelimab Longer-Term Results in Advanced Cutaneous Squamous Cell Carcinoma Presented at ESMO Congress 2024

Consensus revenue estimates increase by 11%

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

New minor risk - Share price stability

Checkpoint Therapeutics, Inc Announces FDA Acceptance of BLA Resubmission of Cosibelimab for the Treatment of Advanced Cutaneous Squamous Cell Carcinoma

Price target increased by 19% to US$21.67

Checkpoint Therapeutics, Inc. announced a financing transaction

Checkpoint Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $12.000001 million.

President recently sold US$50k worth of stock

Checkpoint Therapeutics Announces Alignment with FDA Enabling Upcoming Cosibelimab BLA Resubmission

No longer forecast to breakeven

First quarter 2024 earnings released: US$0.32 loss per share (vs US$0.89 loss in 1Q 2023)

Checkpoint Therapeutics, Inc., Annual General Meeting, May 13, 2024

Insufficient new directors

Full year 2023 earnings: EPS and revenues miss analyst expectations

New major risk - Revenue and earnings growth

Checkpoint Therapeutics, Inc. Appoints Amit Sharma to Its Board as an Independent, Non-Executive Director

Checkpoint Therapeutics, Inc. Receives A Letter from Nasdaq Confirming the Company Was No Longer in Compliance with the Board Independence Rule

Checkpoint Therapeutics, Inc. Receives A Letter from Nasdaq Confirming the Company Was No Longer in Compliance with the Board Independence Rule

New major risk - Financial position

New major risk - Share price stability

Checkpoint Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $14.000001 million.

Checkpoint Therapeutics, Inc. Announces Board Changes, Effective January 31, 2024

Consensus revenue estimates increase by 25%, EPS downgraded

U.S. Food and Drug Administration Issues Complete Response Letter for Checkpoint Therapeutics, Inc.'s Cosibelimab Solely Due to Inspection Findings At Third-Party Manufacturer

Consensus revenue estimates increase by 19%

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

New major risk - Revenue and earnings growth

Checkpoint Therapeutics Announces Publication of Cosibelimab Pivotal Trial Results in the Journal for ImmunoTherapy of Cancer

First quarter 2023 earnings released: US$0.89 loss per share (vs US$1.98 loss in 1Q 2022)

Consensus revenue estimates increase by 41%

Price target decreased by 42% to US$33.50

Consensus revenue estimates decrease by 78%, EPS upgraded

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Forecast breakeven date pushed back to 2025

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target decreased to US$103

Checkpoint Therapeutics, Inc. Submits Biologics License Application to FDA for Cosibelimab as a Treatment for Patients with Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma

Consensus forecasts updated

Forecast to breakeven in 2024

Consensus revenue estimates fall by 26%

Third quarter 2022 earnings released: US$0.12 loss per share (vs US$0.14 loss in 3Q 2021)

We're A Little Worried About Checkpoint Therapeutics' (NASDAQ:CKPT) Cash Burn Rate

Checkpoint: Strong Data, But Comes With Risks

Consensus forecasts updated

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Checkpoint Therapeutics GAAP EPS of -$0.16 in-line, revenue of $0.02M beats by $0.01M

Price target decreased to US$17.60

Checkpoint Therapeutics, Inc. Announces Positive Interim Results from Registration-Enabling Trial of Cosibelimab in Locally Advanced Cutaneous Squamous Cell Carcinoma

Consensus forecasts updated

Is Checkpoint Therapeutics (NASDAQ:CKPT) In A Good Position To Deliver On Growth Plans?

Checkpoint Therapeutics Inc. Receives Pediatric Investigational Plan Waivers for Cosibelimab from the European Medicines Agency and U.K. Medicines & Healthcare Products Regulatory Agency

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Checkpoint Therapeutics, Inc., Annual General Meeting, Jun 15, 2022

Checkpoint Therapeutics: Potential Upside Based On Marketing Application Submissions

Consensus forecasts updated

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

CFO, Corporate Secretary & Treasurer recently sold US$72k worth of stock

Companies Like Checkpoint Therapeutics (NASDAQ:CKPT) Are In A Position To Invest In Growth

CFO, Corporate Secretary & Treasurer recently sold US$93k worth of stock

Checkpoint Therapeutics: Another Buying Opportunity Following Cosibelimab's Impressive Topline Results

Forecast to breakeven in 2024

Checkpoint Therapeutics Announces Positive Topline Results from the Registration-Enabling Trial of Cosibelimab in Metastatic Cutaneous Squamous Cell Carcinoma

Checkpoint Therapeutics, Inc. Announces Initiation of CONTERNO Phase 3 Trial of Cosibelimab Combined with Chemotherapy in Patients with First-Line Non-Squamous Non-Small Cell Lung Cancer

Checkpoint Therapeutics: Pullback Provides Opportunity To Add Ahead Of Cosibelimab's Data Readout

Third quarter 2021 earnings released: US$0.14 loss per share (vs US$0.087 loss in 3Q 2020)

Checkpoint Therapeutics (NASDAQ:CKPT) Is In A Good Position To Deliver On Growth Plans

Second quarter 2021 earnings released: US$0.12 loss per share (vs US$0.09 loss in 2Q 2020)

Consensus revenue estimates fall to US$359.0k

We're Not Very Worried About Checkpoint Therapeutics' (NASDAQ:CKPT) Cash Burn Rate

Checkpoint Therapeutics: Amassing A Position Ahead Of Cosibelimab Data

Checkpoint Therapeutics, Inc.(NasdaqCM:CKPT) dropped from Russell 3000E Index

Checkpoint Therapeutics (CKPT) Investor Presentation - Slideshow

Price target increased to US$15.80

Checkpoint surges 24% on B. Riley buy initiation, 567% upside potential